| Ytd | -29.14% | |
| 1y | -59.16% |
| Open | 0.58 | Prev Close | 0.56 | Low | 0.56 | High | 0.60 | Mkt Cap | 7.61M |
| Vol | 70.59K | Avg Vol | 280.14K | EPS | -0.95 | P/E | N/A | Forward P/E | -3.08 |
| Beta | 1.74 | Short Ratio | 0.55 | Inst. Own | 43.85% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-15 | 50-d Avg | 0.73 | 200-d Avg | 0.78 | 1yr Est | 15.67 |
APRE News
Gainers SCWorx Corp. - Common Stock (NASDAQ:WORX) shares moved upwards by 48.8% to $6.25 during Thu
Company to participate in 2026 Maxim Growth Summit (October 14) and Regional Biotechnology Conferenc
Abstract accepted for oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets an
DOYLESTOWN, Pa., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”
DOYLESTOWN, Pa., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”
Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage
Company Strengthens Global Intellectual Property Portfolio with 28 Issued and 30 Pending Patents Com
Gainers Celularity (NASDAQ:CELU) stock moved upwards by 134.0% to $2.06 during Thursday's regul
Gainers Innovative Eyewear (NASDAQ:LUCY) stock rose 63.6% to $1.12 during Monday's regular sess
Wedbush analyst Robert Driscoll maintains Aprea Therapeutics (NASDAQ:APRE) with a Outperform and
Aprea Therapeutics (NASDAQ:APRE) reported quarterly losses of $(0.07) per share which beat the analy
Enrollment in the ongoing Phase 1 dose escalation ACESOT-1051 trial of oral WEE1 inhibitor APR-1051
SALT LAKE CITY, Aug. 3, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical compa
Next clinical data update from the ongoing Phase 1 dose escalation ACESOT-1051 trial anticipated at
Presentation highlights early clinical activity from ACESOT-1051, including partial responses and st
Aprea Therapeutics (APRE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism ab
DOYLESTOWN, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”,
Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Ana
Pre-Market Stock Futures: Futures are trading modestly higher after a blowout midweek rally spurred
DOYLESTOWN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”
DOYLESTOWN, Pa., April 01, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”
Financing led by Soleus Capital with participation from Vestal Point Capital, Squadron Capital Manag
Confirmed partial response at 220 mg indicates anti-tumor activity of APR-1051 in biomarker-defined
Aprea Therapeutics (NASDAQ: APRE - Get Free Report) will likely be releasing its Q4 2025 results bef
DOYLESTOWN, Pa., March 16, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”
Aprea Therapeutics (NASDAQ: APRE) shares are trading higher on Wednesday as the company announced ad
Tumor Shrinkage of 50% and significant CA-125 biomarker reduction observed at 220 mg dose level Pati
DOYLESTOWN, Pa., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”
On Wednesday, 129 stocks made new 52-week lows.
On Monday, 76 companies set new 52-week lows.
On Monday, 89 stocks made new 52-week lows.
On Friday, 469 companies hit new 52-week lows.